Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 443 across all filing types
Latest filing 2020-09-03 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
ImmuPharma - Conversion of Convertible Security
Share Issue/Capital Change Classification · 1% confidence The document announces the conversion of a convertible security into new ordinary shares, resulting in an increase in the total issued share capital. This action directly relates to changes in the company's capital structure and financing instruments. Based on the definitions, the most appropriate category is 'Capital/Financing Update' (CAP), as it details the issuance of shares resulting from a debt/security conversion.
2020-09-03 English
Placing to raise £6.5 million
Regulatory Filings Classification · 1% confidence The document starts with an 'RNS Number' and is dated 02 September 2020. The content details a 'Placing to raise £6.5 million' through the issuance of new ordinary shares, including details about the placing price, admission to AIM, issuance of warrants, and adjustments to convertible securities. This is a clear announcement regarding a fundraising and capital structure event. This fits the definition of 'Capital/Financing Update' (CAP). Although it is distributed via RNS, the core subject matter is financing, making CAP the most specific classification. It is not a general regulatory filing (RNS) because the subject is highly specific to capital raising.
2020-09-02 English
ImmuPharma - Placing to raise £6.5 million
Share Issue/Capital Change Classification · 1% confidence The document is an announcement titled "Placing to raise £6.5 million" detailing the issuance of new ordinary shares to raise capital. It discusses the mechanics of the share placement, the resulting change in the total issued share capital, the issuance of warrants, and the use of proceeds. This activity directly relates to fundraising, capital structure changes, and the issuance of new shares. This aligns best with the 'Capital/Financing Update' (CAP) or 'Share Issue/Capital Change' (SHA). Since the primary focus is the successful completion of a fundraising round (Placing) involving new share issuance, 'CAP' (Capital/Financing Update) is highly appropriate, as is 'SHA' (Share Issue/Capital Change). Given the context of raising funds via a placement, CAP is often used for the overall financing event, while SHA focuses purely on the share count change. As this is a comprehensive announcement about securing new capital, I will classify it as CAP, as it encompasses the financing aspect more broadly than just the share count change.
2020-09-02 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly labeled with 'RNS Number : 5445X' and contains the header 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification. The presence of 'RNS' branding and the reference to the Financial Conduct Authority (FCA) confirm it is a regulatory filing related to ownership changes. Therefore, the most specific code is MRQ (Major Shareholding Notification).
2020-09-01 English
FDA submission for Special Protocol Assessment
Legal Proceedings Report Classification · 1% confidence The document begins with 'RNS Number : 0862U' and is dated July 27, 2020. It announces a regulatory milestone: the submission of a Special Protocol Assessment (SPA) request to the US FDA by the company's licensing partner regarding the Phase III trial of Lupuzor™. This is a specific corporate update concerning regulatory interaction and clinical trial strategy, not a full financial report (like 10-K or IR) or a general earnings announcement (ER). Since it is a formal announcement disseminated via the RNS system, and it details a specific corporate action/update that doesn't fit perfectly into the other specific categories (like DIRS, DIV, CAP), it falls best under the general Regulatory Filings category (RNS) or potentially a Legal/Regulatory update, but RNS is the most accurate descriptor given the header information and nature of the announcement.
2020-07-27 English
Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients
Legal Proceedings Report Classification · 1% confidence The document announces a significant regulatory milestone: the submission of a Special Protocol Assessment (SPA) request to the US FDA by ImmuPharma's licensing partner regarding the Phase III trial design for Lupuzor™. This announcement details progress in clinical trial strategy and regulatory interaction, which is typical for ongoing drug development updates. It is not a full Annual Report (10-K), an Earnings Release (ER), or a formal Audit Report (AR). Since it concerns specific regulatory submissions and clinical trial progress, it falls under the category of general regulatory or investor information. Given the options, this type of specific, non-financial, non-governance regulatory update that doesn't fit neatly into the other specific categories (like M&A, Dividend, or Director Dealing) is best classified as a general Regulatory Filing (RNS), as it is an announcement of an action taken with a regulatory body (FDA). It is too specific for a general 'Investor Presentation' (IP) and does not fit the definition of 'Legal Proceedings Report' (LTR) as it is proactive regulatory engagement, not litigation.
2020-07-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.